Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 15087285
Harris MB, et al. (2004) Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 287, H560-6 15087285
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S617-p - eNOS (cow)
Modsite: SYKIRFNsVSCSDPL SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S615‑p, eNOS (mouse): S614‑p, eNOS (rat): S614‑p, eNOS (rabbit): S621‑p, eNOS (pig): S617‑p, eNOS (cow): S617‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  endothelial-aorta
Cellular systems studied:  primary cultured cells
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lovastatin increase
wortmannin lovastatin inhibit treatment-induced increase
LY294002 lovastatin inhibit treatment-induced increase
pravastatin increase
wortmannin pravastatin inhibit treatment-induced increase
LY294002 pravastatin inhibit treatment-induced increase
lovastatin increase
wortmannin lovastatin inhibit treatment-induced increase
LY294002 lovastatin inhibit treatment-induced increase
pravastatin increase
wortmannin pravastatin inhibit treatment-induced increase
LY294002 pravastatin inhibit treatment-induced increase

S635-p - eNOS (cow)
Modsite: WRRKRKEsSNTDSAG SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S633‑p, eNOS (mouse): S632‑p, eNOS (rat): S632‑p, eNOS (rabbit): S639‑p, eNOS (pig): S635‑p, eNOS (cow): S635‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  endothelial-aorta
Cellular systems studied:  primary cultured cells
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lovastatin increase
pravastatin increase
KT5720 lovastatin inhibit treatment-induced increase
KT5720 pravastatin inhibit treatment-induced increase

S1179-p - eNOS (cow)
Modsite: TSRIRtQsFsLQERH SwissProt Entrez-Gene
Orthologous residues
eNOS (human): S1177‑p, eNOS (mouse): S1176‑p, eNOS (rat): S1176‑p, eNOS (rabbit): S1183‑p, eNOS (pig): S1179‑p, eNOS (cow): S1179‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  endothelial-aorta
Cellular systems studied:  primary cultured cells
Species studied:  cow
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lovastatin increase
wortmannin lovastatin inhibit treatment-induced increase
LY294002 lovastatin inhibit treatment-induced increase
pravastatin increase
wortmannin pravastatin inhibit treatment-induced increase
LY294002 pravastatin inhibit treatment-induced increase